High-Quality Development Measure 2: Advancing Clinical Research

High-Quality Development Measure 2: Advancing Clinical Research​

In the journey of innovating heavy ion medical technology, the Heavy Ion Center of Gansu Wuwei Cancer Hospital has positioned clinical research as its core engine, adopting a tripartite development model integrating scientific research breakthroughs, clinical practice, and achievements translation to drive iterative upgrades in heavy ion therapy.

The center will initiate eight heavy ion therapy clinical research projects targeting liver cancer, esophageal cancer, lung cancer, breast cancer, cervical cancer, pancreatic cancer, high-grade glioma, and head and neck adenoid cystic carcinoma. For patients enrolled in these studies, the hospital will provide research funding to expert teams, covering the full cost of heavy ion therapy. This initiative creates a mutual empowerment ecosystem, benefiting patients through advanced treatments while advancing technological frontiers.

This innovative model has broken down traditional research barriers, accelerated the establishment of a national standardized protocol for heavy ion therapy in complex cancer fields, and promoted the transformation of clinical treatment technologies for multiple disease types into clinical guidelines and standards. It has provided a "Chinese solution" for the standardized and precision-driven development of heavy ion medical technology globally, and is writing a contemporary answer to safeguarding human health through standardized clinical research.